Reply to the letter to the editor 'Including lynch syndrome in personalized prognostication and follow-up of stage II and III colon cancer' by Sciallero et al

Affiliations

¹ Computational Oncology, Sage Bionetworks, Seattle, USA; Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. Electronic address: rodrigo.dienstmann@sagebase.org.
² Computational Oncology, Sage Bionetworks, Seattle, USA.

Free article

Comment

R Dienstmann et al. Ann Oncol. 2017.

Free article

. 2017 Nov 1;28(11):2889-2890.

doi: 10.1093/annonc/mdx415.

¹ Computational Oncology, Sage Bionetworks, Seattle, USA; Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. Electronic address: rodrigo.dienstmann@sagebase.org.
² Computational Oncology, Sage Bionetworks, Seattle, USA.

No abstract available

Comment on

Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.
Dienstmann R, Mason MJ, Sinicrope FA, Phipps AI, Tejpar S, Nesbakken A, Danielsen SA, Sveen A, Buchanan DD, Clendenning M, Rosty C, Bot B, Alberts SR, Milburn Jessup J, Lothe RA, Delorenzi M, Newcomb PA, Sargent D, Guinney J. Dienstmann R, et al. Ann Oncol. 2017 May 1;28(5):1023-1031. doi: 10.1093/annonc/mdx052. Ann Oncol. 2017. PMID: 28453697 Free PMC article.
Including Lynch syndrome in personalized prognostication and follow-up of stage II and III colon cancer.
Sciallero S, Battistuzzi L, Varesco L. Sciallero S, et al. Ann Oncol. 2017 Oct 1;28(10):2620-2621. doi: 10.1093/annonc/mdx292. Ann Oncol. 2017. PMID: 28945832 No abstract available.